Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267607 | 0.82 | GPR119 (0.44) | GPR119KDM4E | |
| SCHEMBL5993914 | 0.80 | SLC6A2 (0.59) | GPR119MEN1KMT2A | |
| SCHEMBL5992970 | 0.79 | GPR119 (0.46) | GPR119MEN1KMT2AJAK2JAK1 | |
| SCHEMBL3267888 | 0.79 | CYP3A4 (0.42) | GPR119MEN1KMT2A | |
| SCHEMBL5997497 | 0.79 | SLC6A2 (0.45) | GPR119MEN1KMT2A | |
| SCHEMBL5996682 | 0.79 | SLC6A2 (0.59) | GPR119MEN1KMT2A | |
| SCHEMBL3269387 | 0.78 | CYP11B2 (0.46) | GPR119MEN1KMT2A | |
| Acetic Acid SCHEMBL5993263 | 0.78 | SLC6A2 (0.58) | GPR119MEN1KMT2A | |
| SCHEMBL3267959 | 0.77 | MMP13 (0.49) | GPR119KDM4EPKMMEN1KMT2A | |
| SCHEMBL3268175 | 0.74 | GPR119 (0.48) | GPR119MEN1KMT2AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735302-B1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1735302-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005092885-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | GPR119 223/4885OPRM1 72/4885OPRK1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.